Showing results (1951-1960 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 7, 2017
Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibitionMohammad Mehdi Amiri, Forough Golsaz-Shirazi, Tahereh Soltantoyeh, et al.
Investigational New Drugs|January 28, 2020
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinomaDavid C Smith, Matthias Kroiss, Electron Kebebew, et al.
Investigational New Drugs|April 1, 2017
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexedGoushi Matama, Takaaki Tokito, Hiroaki Takeoka, et al.
Investigational New Drugs|March 18, 2019
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?Giandomenico Roviello, Navid Sohbani, Roberto Petrioli, et al.
Investigational New Drugs|January 1, 1985
The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a reviewA Goldin, J M Venditti, R Geran
Investigational New Drugs|November 23, 2018
Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cellsElizabeth Hernandez Marin, Hana Paek, Mei Li, et al.
Investigational New Drugs|March 9, 2019
Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasionFa-An Miao, Kun Chu, Hai-Rong Chen, et al.
Investigational New Drugs|February 23, 2019
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damageHyun-Cheol Kang, Eui Kyu Chie, Hak Jae Kim, et al.
Investigational New Drugs|February 13, 2021
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trialAnas Alshawa, Alexandra Perez Cadena, Bettzy Stephen, et al.
Investigational New Drugs|January 23, 2021
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapyNorikazu Matsuo, Koichi Azuma, Takashi Kojima, et al.
Pageof 372